Search

Advancements in genomic technologies have ushered application of innovative changes into biomedical sciences and clinical medicine. Consequently, these changes have created enormous opportunities to implement precision population/occupational disease prevention and target-specific disease intervention (or personalized medicine). To capture the opportunities, however, it is necessary is to develop novel, especially genomic-based, biomarkers which can provide precise and individualized health risk assessment. In this review, development of the Challenge-comet assay is used as an example to demonstrate how assays need to be validated for its sensitivity, specificity, and functional and quantitative features, and how assays can be used to provide individualized health risk assessment for precision prevention and intervention. Other examples of genomic-based novel biomarkers will also be discussed. Furthermore, no biomarkers can be used alone therefore their integrated usage with other biomarkers and with personal data bases will be discussed. University of Medicine, Pharmacy, Sciences and Technology, Romania; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81673037]; Healthy Aging in Industrial Environment from the Czech Ministry of Education [HAIE CZ.02.1.01/0.0/0.0/16_019/0000798]; EUEuropean Union (EU); EU-Cost ActionEuropean Union (EU)European Cooperation in Science and Technology (COST) [CA 15129] This work was supported by internal funding to WWA from the University of Medicine, Pharmacy, Sciences and Technology, Romania; by grants from the National Natural Science Foundation of China (grant number No. 81673037) to JZX and by the Healthy Aging in Industrial Environment grant HAIE CZ.02.1.01/0.0/0.0/16_019/0000798 from the Czech Ministry of Education and EU to RJS. This project is a part of the EU-Cost Action, CA 15129 (DiMoPEx). WOS:000533634300002 32305282 Q2